Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Revenue Growth %: +15.3%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +15.3%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of $1.99, $1.08 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.56 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- Barclays Reiterates Overweight Rating on Wizz Air Holdings (WIZZ:LN) (WZZAF)
- Barclays Upgrades AutoStore Holdings Ltd (AUTO:NO) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
